Skip to content
Screener

Cytokinetics CYTK Shares (Diluted)

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
893.7M-0.7%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
437.7M+20.4%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
107.1M+12.6%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
57.4M+25.9%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
83.4M+7.0%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
143.7M+52.6%

Other financials

Income statement

See full
Revenue$28.6M-57.1%
Operating income-$179.2M-60.7%
Net income-$198.8M-47.9%
EPS (diluted)-$1.50-33.9%

Balance sheet

See full
Cash & equivalents$255.3M+241%
Total debt$399.0M+31.2%
Total equity-$173.5M+52.9%
Total assets$1.9B+57.0%

Cash flow

See full
Operating cash flow-$159.8M-24.6%
CapEx$4.3M+4.6%
Free cash flow-$164.2M-24.0%

Valuation

See full
Market cap$10.71B+155%
Enterprise value$10.85B+145%
P/S158.2×+109×

Profitability

See full
Operating margin-1,046.1%+1,858pp
Net margin-1,321.1%+8,702pp
FCF margin-858.2%+1,799pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio6.7×-0.1×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338217
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Change in fair value of liabilities related to RPI Transactions2,400(14,600)800(10,700)
Net loss$(198,762)$(134,370)$(404,793)$(295,746)
Net loss per share — basic and diluted$(1.50)$(1.12)$(3.17)$(2.49)
Weighted-average number of shares used in computing net loss per share — basic and diluted132,086119,457127,704118,979
Other comprehensive (loss) gain:
Unrealized loss on available-for-sale securities, net(1,770)(851)(3,608)(1,392)
Foreign currency translation adjustments(444)(852)(848)(1,164)
Comprehensive loss$(200,976)$(136,073)$(409,249)$(298,302)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Cytokinetics's shares (diluted)?
Cytokinetics (CYTK) reported shares (diluted) of 132.1M in Q2 2026.
How has Cytokinetics's shares (diluted) changed year-over-year?
Cytokinetics's shares (diluted) increased by 10.6% year-over-year, from 119.5M to 132.1M.
What is the long-term trend for Cytokinetics's shares (diluted)?
Over 4 years (2021 to 2025), Cytokinetics's shares (diluted) has grown at a 12.3% compound annual growth rate (CAGR), from 300.2M to 478M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Cytokinetics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude